Pasar al contenido principal

ANALISIS DE LOS MECANISMOS ENDOCITICOS DESENCADENADOS POR CD169 EN CELULAS MIELOIDES Y SU CONTRIBUCION A LA DISEMINACION VIRAL

PID2022-139271OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION PRIVADA INSTITUT DE RECERCA SOBRE IMMUNOPATOLOGIES-CAIXA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 15
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Reseña (Review)

Targeting Viral Transcription for HIV Cure Strategies

  • Izquierdo-Pujol, Jon|||0000-0002-5903-9909
  • Puertas, Maria C.|||0000-0002-6750-2318
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
  • Moron-Lopez, Sara|||0000-0003-0800-9205
Combination antiretroviral therapy (ART) suppresses viral replication to undetectable levels, reduces mortality and morbidity, and improves the quality of life of people living with HIV (PWH). However, ART cannot cure HIV infection because it is unable to eliminate latently infected cells. HIV latency may be regulated by different HIV transcription mechanisms, such as blocks to initiation, elongation, and post-transcriptional processes. Several latency-reversing (LRA) and -promoting agents (LPA) have been investigated in clinical trials aiming to eliminate or reduce the HIV reservoir. However, none of these trials has shown a conclusive impact on the HIV reservoir. Here, we review the cellular and viral factors that regulate HIV-1 transcription, the potential pharmacological targets and genetic and epigenetic editing techniques that have been or might be evaluated to disrupt HIV-1 latency, the role of miRNA in post-transcriptional regulation of HIV-1, and the differences between the mechanisms regulating HIV-1 and HIV-2 expression.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Protein Nanoparticles for Targeted SARS-CoV-2 Trapping and Neutralization

  • Fornt Suñé, Marc|||0000-0003-1197-2836
  • Puertas, Maria C.|||0000-0002-6750-2318
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
  • Garcia-Pardo, Javier|||0000-0001-9179-6371
  • Ventura, Salvador|||0000-0002-9652-6351
The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), continues to challenge global health despite widespread vaccination efforts, underscoring the need for innovative strategies to combat emerging infectious diseases effectively. Herein, LCB1-NPs and LCB3-NPs are engineered as a novel class of protein-only nanoparticles formed through coiled coil-driven self-assembly and tailored to interact specifically with the SARS-CoV-2 spike protein. The multivalency of LCB1-NPs and LCB3-NPs offers a strategy for efficiently targeting and neutralizing SARS-CoV-2 both in solution and when immobilized on surfaces. It is demonstrated that LCB1-NPs and LCB3-NPs bind to the SARS-CoV-2 spike protein's receptor-binding domain (RBD) with high affinity, effectively blocking the entry of SARS-CoV-2 virus-like particles into angiotensin-converting enzyme 2 (ACE2)-coated human cells. The cost-effectiveness, scalability, and straightforward production process of these protein nanoparticles make them suitable for developing novel anti-viral materials. Accordingly, it is shown how these nanostructures can be packed into columns to build up economic and highly potent trapping devices for SARS-CoV-2 adsorption.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Proteomics of circulating extracellular vesicles reveals diverse clinical presentations of COVID-19 but fails to identify viral peptides

  • Gualdrón-López, Melisa|||0000-0002-8202-6751
  • Ayllon-Hermida, Alberto|||0000-0002-9566-6934
  • Cortés Serra, Núria|||0000-0001-5396-3757
  • Resa-Infante, Patricia|||0000-0002-1727-592X
  • Bech-Serra, Joan-Josep|||0000-0003-3486-781X
  • Aparici-Herraiz, Iris|||0000-0002-6014-8221
  • Nicolau Fernández, Marc|||0000-0001-7211-796X
  • Erkizia, Itziar|||0000-0003-1244-8972
  • Gutierrez-Chamorro, Lucia
  • Marfil, Sílvia|||0000-0003-0139-5000
  • Pradenas, Edwards|||0000-0001-5162-8920
  • Ávila Nieto, Carlos
  • Cucurull, Bernat
  • Montaner-Tarbés, Sergio
  • Muelas, Magdalena
  • Sotil, Ruth
  • Ballana, Ester|||0000-0002-5215-7363
  • Urrea, Víctor|||0000-0002-2577-856X
  • Fraile, Lorenzo|||0000-0002-8980-5862
  • Montoya, Maria|||0000-0002-5703-7360
  • Vergara-Alert, Júlia|||0000-0001-7484-444X
  • Segalés Coma, Joaquim|||0000-0002-1539-7261
  • Carrillo, Jorge|||0000-0003-0221-5948
  • Izquierdo Useros, Nuria|||0000-0002-1039-1821
  • Blanco, Julià|||0000-0002-2225-0217
  • Fernandez-Becerra, Carmen|||0000-0001-5154-0013
  • De La Torre, Carolina
  • Pinazo, Maria-Jesus|||0000-0002-4237-1075
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
  • Del Portillo, Hernando A.|||0000-0002-5278-3452
Extracellular vesicles (EVs) released by virus-infected cells have the potential to encapsulate viral peptides, a characteristic that could facilitate vaccine development. Furthermore, plasma-derived EVs may elucidate pathological changes occurring in distal tissues during viral infections. We hypothesized that molecular characterization of EVs isolated from COVID-19 patients would reveal peptides suitable for vaccine development. Blood samples were collected from three cohorts: severe COVID-19 patients (G1), mild/asymptomatic cases (G2), and SARS-CoV-2-negative healthcare workers (G3). Samples were obtained at two time points: during the initial phase of the pandemic in early 2020 (m0) and eight months later (m8). Clinical data analysis revealed elevated inflammatory markers in G1. Notably, non-vaccinated individuals in G1 exhibited increased levels of neutralizing antibodies at m8, suggesting prolonged exposure to viral antigens. Proteomic profiling of EVs was performed using three distinct methods: immunocapture (targeting CD9), ganglioside-capture (utilizing Siglec-1) and size-exclusion chromatography (SEC). Contrary to our hypothesis, this analysis failed to identify viral peptides. These findings were subsequently validated through Western blot analysis targeting the RBD of the SARS-CoV-2 Spike protein's and comparative studies using samples from experimentally infected Syrian hamsters. Furthermore, analysis of the EV cargo revealed a diverse molecular profile, including components involved in the regulation of viral replication, systemic inflammation, antigen presentation, and stress responses. These findings underscore the potential significance of EVs in the pathogenesis and progression of COVID-19.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Sustained HIV remission after allogeneic hematopoietic stem cell transplantation with wild-type CCR5 donor cells

  • Sáez-Cirión, Asier|||0000-0003-2406-7536
  • Mamez, Anne-Claire
  • Avettand-Fenoel, Véronique|||0000-0002-7022-2990
  • Nabergoj, Mitja|||0000-0003-2842-3198
  • Passaes, Caroline|||0000-0002-0813-2521
  • Thoueille, Paul|||0000-0002-2305-4277
  • Decosterd, Laurent|||0000-0002-9840-1325
  • Hentzien, Maxime|||0000-0003-2729-9420
  • Perdomo-Celis, Federico|||0000-0003-0119-8306
  • Salgado, Maria|||0000-0003-1551-7216
  • Nijhuis, Monique|||0000-0001-6610-8282
  • Mélard, Adeline|||0000-0003-1207-0201
  • Gardiennet, Elise|||0000-0003-4654-142X
  • Lorin, Valerie|||0000-0003-1760-1585
  • Monceaux, Valérie|||0000-0002-8599-2146
  • Chapel, Anaïs
  • Gourvès, Maël
  • Lechartier, Marine
  • Mouquet, Hugo
  • Wensing, Annemarie|||0000-0003-3790-8891
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
  • Yerly, Sabine|||0000-0003-1668-696X
  • Rougemont, Mathieu
  • Calmy, Alexandra|||0000-0002-1137-6826
HIV cure has been reported for five individuals who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) with cells from CCR5Δ32 homozygous donors. By contrast, viral rebound has occurred in other people living with HIV who interrupted antiretroviral treatment after undergoing allo-HSCT, with cells mostly from wild-type CCR5 donors. Here we report the case of a male individual who has achieved durable HIV remission following allo-HSCT with cells from an unrelated HLA-matched (9 of 10 matching for HLA-A, HLA-B, HLA-C, HLA-DRB1 and HLA-DQB1 alleles) wild-type CCR5 donor to treat an extramedullary myeloid tumor. To date, plasma viral load has remained undetectable for 32 months after the interruption of antiretroviral treatment. Treatment with ruxolitinib has been maintained during this period to treat chronic graft-versus-host disease. Low levels of proviral DNA were detected sporadically after allo-HSCT, including defective but not intact HIV DNA. No virus could be amplified in cultures of CD4 T cells obtained after antiretroviral treatment interruption, while CD4 T cells remained susceptible to HIV-1 infection in vitro. Declines in HIV antibodies and undetectable HIV-specific T cell responses further corroborate the absence of viral rebound after antiretroviral treatment interruption. These results suggest that HIV remission could be achieved in the context of allo-HSCT with wild-type CCR5.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Exceptional, naturally occurring HIV-1 control, Insight into a functional cure

  • Salgado, Maria|||0000-0003-1551-7216
  • Migueles, S.A.
  • Yu, X.G.
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
Exceptional elite controllers represent an extremely rare group of people with HIV-1 (PWH) who exhibit spontaneous, high-level control of viral replication below the limits of detection in sensitive clinical monitoring assays and without disease progression in the absence of antiretroviral therapy for prolonged periods, frequently exceeding 25 years. Here, we discuss the different cases that have been reported in the scientific literature, their unique genetic, virological, and immunological characteristics, and their relevance as the best model for the functional cure of HIV-1.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Assessing advances in three decades of clinical antiretroviral therapy on the HIV-1 reservoir

  • González-Navarro, Irene|||0000-0002-4567-766X
  • Urrea, Víctor|||0000-0002-2577-856X
  • Gálvez, Cristina|||0000-0002-2286-6193
  • García Guerrero, María del Carmen|||0000-0001-7651-7629
  • Moron-Lopez, Sara|||0000-0003-0800-9205
  • Puertas, Maria C.|||0000-0002-6750-2318
  • Grau, Eulàlia|||0000-0002-2442-9165
  • Mothe, Beatriz|||0000-0001-9975-407X
  • Bailón, Lucía|||0000-0001-7277-9314
  • Miranda, Cristina
  • García, Felipe|||0000-0001-7658-5832
  • Leal, Lorna|||0000-0001-7887-6027
  • Vandekerckhove, Linos|||0000-0002-8600-1631
  • Marconi, Vincent C.
  • Sekaly, Rafick P.
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
  • Salgado, Maria|||0000-0003-1551-7216
Antiretroviral therapy (ART) has improved the clinical management of HIV-1 infection. However, little is known about how the latest ART recommendations affect the heterogeneity of the HIV-1 reservoir size. We used a complete statistical approach to outline parameters underlying the diversity in HIV-1 reservoir size in a cohort of 892 people with HIV-1 (PWH) on suppressive ART for more than 3 years. Total HIV-1-DNA levels were measured in PBMCs using digital droplet PCR (ddPCR). We classified 179 (20%) participants as being low viral reservoir treated (LoViReT) (<50 HIV-1-DNA copies/10 6 PBMCs). Twenty variables were collected to explore their association with the LoViReT phenotype using machine learning approaches. LoViReT status was closely associated with higher nadir CD4, lower zenith pre-ART viral load, lower CD4 recovery, shorter time from diagnosis to undetectable viral load, and initiation of treatment with an integrase inhibitor-containing (InSTI-containing) regimen. Initiation of ART with any InSTI was also linked with a shorter time to undetectable viremia. Locally estimated scatterplot smoothing (LOESS) regression revealed a progressive reduction in the size of the HIV-1 reservoir in individuals who started ART after 2007. Similarly, a higher nadir CD4 and a shorter time to undetectable viremia were observed when treatment was initiated after that year. Our findings demonstrate that the progressive implementation of earlier, universal treatment at diagnosis and the use of InSTIs affected the size of the HIV-1 reservoir. Our work shows that effective management of infection is the first step toward reducing the reservoir and brings us closer to achieving a cure. NIH; Division of AIDS at the National Institute of Allergy and Infectious Diseases (NIAID), NIH; Merck Sharp & Dohme. In this manuscript, we show that the progressive implementation of earlier, universal treatment at diagnosis and the use of InSTIs affect the size of the HIV-1 reservoir in the population of PWH.
IRTA Pubpro. Open Digital Archive
Publicación Artículo científico (JournalArticle)

Proteomics of circulating extracellular vesicles reveals diverse clinical presentations of COVID-19 but fails to identify viral peptides

  • Gualdrón-López, Melisa
  • Ayllon-Hermida, Alberto
  • Cortes-Serra, Núria
  • Resa-Infante, Patricia
  • Bech-Serra, Joan Josep
  • Aparici-Herraiz, Iris
  • Nicolau-Fernandez, Marc
  • Erkizia, Itziar
  • Gutierrez-Chamorro, Lucia
  • Marfil, Silvia
  • Pradenas, Edwards
  • Ávila Nieto, Carlos
  • Cucurull, Bernat
  • Montaner-Tarbés, Sergio
  • Muelas, Magdalena
  • Sotil, Ruth
  • Ballana, Ester
  • Urrea, Victor
  • Fraile, Lorenzo
  • Montoya, Maria
  • Vergara-Alert, Júlia
  • Segalés, Joaquim
  • Carrillo, Jorge
  • Izquierdo-Useros, Nuria
  • Blanco, Julià
  • Fernandez-Becerra, Carmen
  • de La Torre, Carolina
  • Pinazo, Maria-Jesus
  • Martinez-Picado, Javier
  • del Portillo, Hernando A.
Extracellular vesicles (EVs) released by virus-infected cells have the potential to encapsulate viral peptides, a characteristic that could facilitate vaccine development. Furthermore, plasma-derived EVs may elucidate pathological changes occurring in distal tissues during viral infections. We hypothesized that molecular characterization of EVs isolated from COVID-19 patients would reveal peptides suitable for vaccine development. Blood samples were collected from three cohorts: severe COVID-19 patients (G1), mild/asymptomatic cases (G2), and SARS-CoV-2-negative healthcare workers (G3). Samples were obtained at two time points: during the initial phase of the pandemic in early 2020 (m0) and eight months later (m8). Clinical data analysis revealed elevated inflammatory markers in G1. Notably, non-vaccinated individuals in G1 exhibited increased levels of neutralizing antibodies at m8, suggesting prolonged exposure to viral antigens. Proteomic profiling of EVs was performed using three distinct methods: immunocapture (targeting CD9), ganglioside-capture (utilizing Siglec-1) and size-exclusion chromatography (SEC). Contrary to our hypothesis, this analysis failed to identify viral peptides. These findings were subsequently validated through Western blot analysis targeting the RBD of the SARS-CoV-2 Spike protein’s and comparative studies using samples from experimentally infected Syrian hamsters. Furthermore, analysis of the EV cargo revealed a diverse molecular profile, including components involved in the regulation of viral replication, systemic inflammation, antigen presentation, and stress responses. These findings underscore the potential significance of EVs in the pathogenesis and progression of COVID-19., The author(s) declare financial support was received for the research, authorship, and/or publication of this article. The proteomics of EVs isolated by CD9 was performed at the proteomics facility of Utrecht (Netherlands) as part of an EPIC-XS grant (0000205) to CT and HP. The proteomics analyses of EVs isolated by SEC were performed in the IJC Proteomic unit, which is part of the of Proteored, PRB3 and is supported by grant PT17/0019, of the PE I+D+i 2013-2016, funded by ISCIII and ERDF”. The CRG/UPF Proteomics Unit is part of the Spanish Infrastructure for Omics Technologies (ICTS OmicsTech), and it is supported by “Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement de la Generalitat de Catalunya” (2017SGR595). We thank Foundation Dormeur for financial support for the acquisition of the QuantStudio-5 real time PCR system. JM-P was supported by the Spanish Ministry of Science,Innovation and Universities (grants PID2022-139271OB-I00 and CB21/13/00063, Spain), and Fundació La Marató de TV3 (grant 202120-30-31-32, Spain). Funded in part by the European Union. The PCR-4-ALL and UNDINE projects have received funding under the Horizon Europe research and innovation programme (grant agreement No 101095606 and No 101057100 respectively). CF-B and HP acknowledge support from the Spanish Ministry of Science and Innovation (MICINN) (PID2022- 142908OB-I00) and support from the grant CEX2023-0001290-S funded by MCIN/AEI/10.13039/501100011033, and support from the Generalitat de Catalunya through the CERCA Program. This research is part of the ISGlobal’s Program on the Molecular Mechanisms of Malaria which is partially supported by the Fundación Ramón Areces. We also acknowledged the internal funding from IrsiCaixa through the crowdfunding initiative YoMeCorono (JM-P) and ISGlobal (HP) to initiate these studies., info:eu-repo/semantics/publishedVersion
Repositori Obert UdL
Publicación Artículo científico (JournalArticle)

Proteomics of circulating extracellular vesicles reveals diverse clinical presentations of COVID-19 but fails to identify viral peptides

  • Gualdrón-López, Melisa
  • Ayllon Hermida, Alberto
  • Cortes Serra, Nuria
  • Resa Infante, Patricia
  • Bech Serra, Joan Josep
  • Aparici Herraiz, Iris
  • Nicolau Fernández, Marc
  • Erkizia, Itziar
  • Gutierrez Chamorro, Lucia
  • Marfil, Silvia
  • Pradenas, Edwards
  • Avila Nieto, Carlos
  • Cucurull, Bernat
  • Montaner Tarbes, Sergio Roberto
  • Fraile Sauce, Lorenzo José
Extracellular vesicles (EVs) released by virus-infected cells have the potential to encapsulate viral peptides, a characteristic that could facilitate vaccine development. Furthermore, plasma-derived EVs may elucidate pathological changes occurring in distal tissues during viral infections. We hypothesized that molecular characterization of EVs isolated from COVID-19 patients would reveal peptides suitable for vaccine development. Blood samples were collected from three cohorts: severe COVID-19 patients (G1), mild/asymptomatic cases (G2), and SARS-CoV-2-negative healthcare workers (G3). Samples were obtained at two time points: during the initial phase of the pandemic in early 2020 (m0) and eight months later (m8). Clinical data analysis revealed elevated inflammatory markers in G1. Notably, non-vaccinated individuals in G1 exhibited increased levels of neutralizing antibodies at m8, suggesting prolonged exposure to viral antigens. Proteomic profiling of EVs was performed using three distinct methods: immunocapture (targeting CD9), ganglioside-capture (utilizing Siglec-1) and size-exclusion chromatography (SEC). Contrary to our hypothesis, this analysis failed to identify viral peptides. These findings were subsequently validated through Western blot analysis targeting the RBD of the SARS-CoV-2 Spike protein's and comparative studies using samples from experimentally infected Syrian hamsters. Furthermore, analysis of the EV cargo revealed a diverse molecular profile, including components involved in the regulation of viral replication, systemic inflammation, antigen presentation, and stress responses. These findings underscore the potential significance of EVs in the pathogenesis and progression of COVID-19., The author(s) declare financial support was received for the research, authorship, and/or publication of this article. The proteomics of EVs isolated by CD9 was performed at the proteomics facility of Utrecht (Netherlands) as part of an EPIC-XS grant (0000205) to CT and HP. The proteomics analyses of EVs isolated by SEC were performed in the IJC Proteomic unit, which is part of the of Proteored, PRB3 and is supported by grant PT17/0019, of the PE I+D+i 2013-2016, funded by ISCIII and ERDF”. The CRG/UPF Proteomics Unit is part of the Spanish Infrastructure for Omics Technologies (ICTS OmicsTech), and it is supported by “Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement de la Generalitat de Catalunya” (2017SGR595). We thank Foundation Dormeur for financial support for the acquisition of the QuantStudio-5 real time PCR system. JM-P was supported by the Spanish Ministry of Science,Innovation and Universities (grants PID2022-139271OB-I00 and CB21/13/00063, Spain), and Fundació La Marató de TV3 (grant 202120-30-31-32, Spain). Funded in part by the European Union. The PCR-4-ALL and UNDINE projects have received funding under the Horizon Europe research and innovation programme (grant agreement No 101095606 and No 101057100 respectively). CF-B and HP acknowledge support from the Spanish Ministry of Science and Innovation (MICINN) (PID2022- 142908OB-I00) and support from the grant CEX2023-0001290-S funded by MCIN/AEI/10.13039/501100011033, and support from the Generalitat de Catalunya through the CERCA Program. This research is part of the ISGlobal’s Program on the Molecular Mechanisms of Malaria which is partially supported by the Fundación Ramón Areces. We also acknowledged the internal funding from IrsiCaixa through the crowdfunding initiative YoMeCorono (JM-P) and ISGlobal (HP) to initiate these studies.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Massive endocytosis mechanisms are involved in uptake of HIV-1 particles by monocyte-derived dendritic cells

  • Laguía, Fernando
  • Chojnacki, Jakub
  • Erkizia, Itziar
  • Geli, María Isabel
  • Enrich, Carlos
  • Martinez-Picado. Javier
  • Resa-Infante, Patricia
[Introduction]: HIV-1 exploits dendritic cells (DCs) to spread throughout the body via specific recognition of gangliosides present on the viral envelope by the CD169/Siglec-1 membrane receptor. This interaction triggers the internalization of HIV-1 within a structure known as the sac-like compartment. While the mechanism underlying sac-like compartment formation remains elusive, prior research indicates that the process is clathrin-independent and cell membrane cholesterol–dependent and involves transient disruption of cortical actin. Here, we investigate the potential involvement of massive endocytosis (MEND) in this process., [Methods]: We used live cell confocal imaging to measure the dimensions and dynamics of the compartment. We assessed the role of actin and cholesterol in fixed and live cells using confocal microscopy and evaluated the effect of PI3K and protein palmytoilation inhibitors during viral uptake., [Results]: Our data demonstrate extensive plasma membrane invagination based on sac-like compartment dimensions (2.9 μm in diameter and 20 μm3 in volume). We showed that the cholesterol concentration doubles within the regions of viral uptake, suggesting lipid-phase separation, and that development of the sac-like compartment is accompanied by transient depolarization of cortical actin. Moreover, we observed that protein palmitoylation and PI3K inhibition reduce the sac-like compartment formation rate from 70% to 20% and 40%, respectively., [Conclusions]: Our results indicate the involvement of MEND mechanisms during sac-like compartment formation., The authors’ laboratories were supported by funding from the Spanish Ministry of Science and Innovation (grants PID2022-139271OB-I00 and CB21/13/00063, Spain), NIH/NIAID (1UM1AI164561-01 and 1P01AI178376-01, United States of America), Generalitat de València (grant PROMETEO/2021/036, Spain), and Grifols (Spain)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Proteomics of circulating extracellular vesicles reveals diverse clinical presentations of COVID-19 but fails to identify viral peptides

  • Gualdrón-López, Melisa
  • Ayllon-Hermida, Alberto
  • Cortes-Serra, Núria
  • Resa-Infante, Patricia
  • Bech-Serra, Joan Josep
  • Aparici-Herraiz, Iris
  • Nicolau-Fernandez, Marc
  • Erkizia, Itziar
  • Gutierrez-Chamorro, Lucia
  • Marfil, Silvia
  • Pradenas, Edwards
  • Ávila Nieto, Carlos
  • Cucurull, Bernat
  • Montaner-Tarbés, Sergio
  • Muelas, Magdalena
  • Sotil, Ruth
  • Ballana, Ester
  • Urrea, Victor
  • Fraile, Lorenzo
  • Montoya, María
  • Vergara, Julia
  • Segales, Joaquim
  • Carrillo, Jorge
  • Izquierdo-Useros, Nuria
  • Blanco, Julià
  • Fernandez-Becerra, Carmen
  • Torre, Carolina de la
  • Pinazo, Maria-Jesus
  • Martinez-Picado, Javier
  • Del Portillo, Hernando A.
Extracellular vesicles (EVs) released by virus-infected cells have the potential to encapsulate viral peptides, a characteristic that could facilitate vaccine development. Furthermore, plasma-derived EVs may elucidate pathological changes occurring in distal tissues during viral infections. We hypothesized that molecular characterization of EVs isolated from COVID-19 patients would reveal peptides suitable for vaccine development. Blood samples were collected from three cohorts: severe COVID-19 patients (G1), mild/asymptomatic cases (G2), and SARS-CoV-2-negative healthcare workers (G3). Samples were obtained at two time points: during the initial phase of the pandemic in early 2020 (m0) and eight months later (m8). Clinical data analysis revealed elevated inflammatory markers in G1. Notably, non-vaccinated individuals in G1 exhibited increased levels of neutralizing antibodies at m8, suggesting prolonged exposure to viral antigens. Proteomic profiling of EVs was performed using three distinct methods: immunocapture (targeting CD9), ganglioside-capture (utilizing Siglec-1) and size-exclusion chromatography (SEC). Contrary to our hypothesis, this analysis failed to identify viral peptides. These findings were subsequently validated through Western blot analysis targeting the RBD of the SARS-CoV-2 Spike protein's and comparative studies using samples from experimentally infected Syrian hamsters. Furthermore, analysis of the EV cargo revealed a diverse molecular profile, including components involved in the regulation of viral replication, systemic inflammation, antigen presentation, and stress responses. These findings underscore the potential significance of EVs in the pathogenesis and progression of COVID-19., The author(s) declare financial support was received for the research, authorship, and/or publication of this article. The proteomics of EVs isolated by CD9 was performed at the proteomics facility of Utrecht (Netherlands) as part of an EPIC-XS grant (0000205) to CT and HP. The proteomics analyses of EVs isolated by SEC were performed in the IJC Proteomic unit, which is part of the of Proteored, PRB3 and is supported by grant PT17/0019, of the PE I+D+i 2013-2016, funded by ISCIII and ERDF”. The CRG/UPF Proteomics Unit is part of the Spanish Infrastructure for Omics Technologies (ICTS OmicsTech), and it is supported by “Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement de la Generalitat de Catalunya” (2017SGR595). We thank Foundation Dormeur for financial support for the acquisition of the QuantStudio-5 real time PCR system. JM-P was supported by the Spanish Ministry of Science,Innovation and Universities (grants PID2022-139271OB-I00 and CB21/13/00063, Spain), and Fundació La Marató de TV3 (grant 202120-30-31-32, Spain). Funded in part by the European Union. The PCR-4-ALL and UNDINE projects have received funding under the Horizon Europe research and innovation programme (grant agreement No 101095606 and No 101057100 respectively). CF-B and HP acknowledge support from the Spanish Ministry of Science and Innovation (MICINN) (PID2022- 142908OB-I00) and support from the grant CEX2023-0001290-S funded by MCIN/AEI/10.13039/501100011033, and support from the Generalitat de Catalunya through the CERCA Program. This research is part of the ISGlobal’s Program on the Molecular Mechanisms of Malaria which is partially supported by the Fundación Ramón Areces. We also acknowledged the internal funding from IrsiCaixa through the crowdfunding initiative YoMeCorono (JM-P) and ISGlobal (HP) to initiate these studies., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

HIV-1 envelope glycoprotein modulates CXCR4 clustering and dynamics on the T cell membrane

  • Quijada-Freire, Adriana
  • Santiago, César
  • García-Cuesta, Eva María
  • Soler Palacios, Blanca
  • Gardeta, Sofia R.
  • San Sebastian, Enara
  • Armendariz- Burgoa, Eva
  • Puertas, Maria Carmen
  • Villares, Ricardo
  • Garaigorta, Urtzi
  • Luis Ignacio González- Granado
  • Rodríguez-Frade, José Miguel
  • Jakub Chojnacki
  • Javier Martinez-Picado
  • Mellado, Mario
HIV-1 entry into susceptible cells requires the dynamic interaction of its envelope (Env) glycoprotein with the host cell receptor CD4 and a co-receptor, either CCR5 or CXCR4. While the core molecular mechanisms driving Env-receptor interactions and subsequent membrane fusion are well characterized, the precise nanoscale spatial reorganization of these co-receptors at the viral binding site remains poorly defined. In this study, we employed single-particle tracking total internal reflection fluorescence (SPT-TIRF) microscopy to quantitatively analyze nanoscale organizational changes of CXCR4 on the surface of human CD4+ T cells following binding by X4-tropic HIV-1. Our data reveal that both recombinant X4-gp120 and virus-like particles expressing physiological levels of X4 Env proteins (gp120 and gp41) promote CXCR4 clustering, a phenomenon linked to cell infection. Furthermore, these ligands induced oligomerization of CXCR4R334X, a naturally occurring mutant associated with WHIM syndrome that supports HIV-1 infection, but fails to oligomerize in response to CXCL12. Our findings establish a link between CXCR4 clustering and HIV-1 infection, enhancing our understanding of the initial events in viral attachment and entry. These results further suggest that HIV-1 depends on a specific spatial arrangement of co-receptors, distinct from that induced by their natural chemokine ligands, highlighting the critical role of cell-surface receptor spatial organization in dictating cellular function., Spanish National Plan for Scientific and Technical Research and Innovation (PID2020-114980RB-I00) Fundación para el Conocimiento Madri+d (CAM20_CNB_AI_07) Federación Española de Enfermedades Raras (FIS PI21/01642) Spanish National Plan for Scientific and Technical Research and Innovation (PID2023-146301OB-I00) Spanish National Plan for Scientific and Technical Research and Innovation (PID2022-140651NB-I00) Spanish National Plan for Scientific and Technical Research and Innovation (PID2022-139271OB-I00) Centro de Investigación Biotecnológica en Red de Enfermedades Infecciosas (CB21/13/00063) Centro Nacional de Biotecnología (SEV-2017-0712) Spanish National Plan for Scientific and Technical Research and Innovation (PRE2018-083201) Spanish National Plan for Scientific and Technical Research and Innovation (PRE2019-087966) Spanish National Plan for Scientific and Technical Research and Innovation (PRE2022-000847), Peer reviewed, Modelo experimental alternativo-NAM, in vitro - Tipos celulares
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Humanized FLT3 mice display enhanced tissue engraftment and support HIV‑1 persistence and rebound

  • Resa-Infante, Patricia
  • Piñol, Patricia
  • Laguía, Fernando
  • Campos-Gonzalez, Gerard
  • Cobos, Àlex
  • Urrea, Victor
  • Garcia-Guerrero, Maria del Carmen
  • Rosales-Salgado, Yaiza
  • Cid, Marina
  • Díaz-Pedroza, Jorge
  • Shultz, Leonard D
  • Yin, Voot
  • Brehm, Michael A.
  • Soper, Brian
  • Salgado, María
  • Martinez-Picado, Javier
Despite advances in antiretroviral therapy (ART), HIV-1 cure efforts remain hindered by viral persistence in long-lived myeloid cells and immune-privileged tissues that are poorly accessible and therefore unlikely to be assessed in human clinical trials. Consequently, robust research platforms, such as immune-cell humanized mice, are needed to bridge preclinical and clinical HIV research. However, previously described humanized mouse models often show incomplete hematopoietic development, particularly showing low levels of NK or myeloid cells. Herein, we evaluate a humanized FLT3 mouse model that develops NK cells, myeloid progenitors, monocytes, and both conventional (cDCs) and plasmacytoid dendritic cells (pDCs), and assessed its capacity to support HIV-1 infection, persistence, and viral rebound. Human cord blood derived CD34+ hematopoietic stem cells (HSC) were engrafted in FLT3 (Hu-FLT3) and NSG (Hu-NSG) mouse strains for comparison. While Hu-NSG and Hu-FLT3 mice showed comparable human lymphocyte levels, the proportion of myeloid-enriched populations, including monocytes, pDCs and cDCs, was three-fold higher in Hu-FLT3 mice (16.2%) than in Hu-NSG mice (5.6%), and the proportion of NK cells was six-fold higher (12.8% vs. 1.9%). Both strains supported HIV-1 infection, maintained viral replication for 17 weeks in untreated animals, and had detectable proviral DNA in peripheral blood, bone marrow and spleen. Oral ART reduced plasma HIV-1 RNA to undetectable levels within four weeks in both strains. After treatment discontinuation, viral rebound occurred within three weeks and approached pre-ART levels, consistent with rebound kinetics observed after treatment interruption in people living with HIV (PLWH). Human immune cells and HIV-1 RNA were more abundant in tissues from Hu-FLT3 mice than in Hu-NSG mice. This study establishes Hu‑FLT3 mice as a novel, robust and accessible in vivo platform to investigate potential HIV cure and persistence‑targeting interventions with translational relevance to human therapeutic development thanks to the improved and more complete human immune repertoire in Hu-FLT3., The authors’ laboratories were supported by funding from the Spanish Ministry of Science and Innovation (grants PID2022-139271OB-I00 and CB21/13/00063, Spain), Generalitat de Catalunya (CERCA program and 2021-SGR-00452) NIH/NIAID (1UM1AI164561-01 and 1P01AI178376-01, United States of America), and Grifols (Spain). FL and GC-G were supported by PhD fellowships (PRE2020-095004 and PRE2021-100501, respectively) from Spanish Ministry of Science and Innovation. MS was supported by the Miguel Servet Fellowship Program (CP22/00038) and I+D+I Grant (PID2023-147320OB-I00) from the Spanish Ministry of Science and Innovation. MAB and LDS were supported by funding from NIH (R24OD036199) and by the Barbara D. Cammett Breakthrough T1D Center of Excellence in New England of the Breakthrough T1D Foundation (4-COE-2025-1751-A-N)., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Proteomics of circulating extracellular vesicles reveals diverse clinical presentations of COVID-19 but fails to identify viral peptides

  • Gualdrón-López, Melisa
  • Ayllon-Hermida, Alberto
  • Cortes-Serra, Núria
  • Resa-Infante, Patricia
  • Bech-Serra, Joan Josep
  • Aparici-Herraiz, Iris
  • Nicolau-Fernandez, Marc
  • Erkizia, Itziar
  • Gutierrez-Chamorro, Lucia
  • Marfil, Silvia
  • Pradenas, Edwards
  • Ávila Nieto, Carlos
  • Cucurull, Bernat
  • Montaner-Tarbés, Sergio
  • Muelas, Magdalena
  • Sotil, Ruth
  • Ballana, Ester
  • Urrea, Victor
  • Fraile, Lorenzo
  • Montoya, Maria
  • Vergara-Alert, Júlia
  • Segalés, Joaquim
  • Carrillo, Jorge
  • Izquierdo-Useros, Nuria
  • Blanco, Julià
  • Fernandez-Becerra, Carmen
  • de La Torre, Carolina
  • Pinazo, Maria-Jesus
  • Martinez-Picado, Javier
  • del Portillo, Hernando A.
Extracellular vesicles (EVs) released by virus-infected cells have the potential to encapsulate viral peptides, a characteristic that could facilitate vaccine development. Furthermore, plasma-derived EVs may elucidate pathological changes occurring in distal tissues during viral infections. We hypothesized that molecular characterization of EVs isolated from COVID-19 patients would reveal peptides suitable for vaccine development. Blood samples were collected from three cohorts: severe COVID-19 patients (G1), mild/asymptomatic cases (G2), and SARS-CoV-2-negative healthcare workers (G3). Samples were obtained at two time points: during the initial phase of the pandemic in early 2020 (m0) and eight months later (m8). Clinical data analysis revealed elevated inflammatory markers in G1. Notably, non-vaccinated individuals in G1 exhibited increased levels of neutralizing antibodies at m8, suggesting prolonged exposure to viral antigens. Proteomic profiling of EVs was performed using three distinct methods: immunocapture (targeting CD9), ganglioside-capture (utilizing Siglec-1) and size-exclusion chromatography (SEC). Contrary to our hypothesis, this analysis failed to identify viral peptides. These findings were subsequently validated through Western blot analysis targeting the RBD of the SARS-CoV-2 Spike protein’s and comparative studies using samples from experimentally infected Syrian hamsters. Furthermore, analysis of the EV cargo revealed a diverse molecular profile, including components involved in the regulation of viral replication, systemic inflammation, antigen presentation, and stress responses. These findings underscore the potential significance of EVs in the pathogenesis and progression of COVID-19., The author(s) declare financial support was received for the research, authorship, and/or publication of this article. The proteomics of EVs isolated by CD9 was performed at the proteomics facility of Utrecht (Netherlands) as part of an EPIC-XS grant (0000205) to CT and HP. The proteomics analyses of EVs isolated by SEC were performed in the IJC Proteomic unit, which is part of the of Proteored, PRB3 and is supported by grant PT17/0019, of the PE I+D+i 2013-2016, funded by ISCIII and ERDF”. The CRG/UPF Proteomics Unit is part of the Spanish Infrastructure for Omics Technologies (ICTS OmicsTech), and it is supported by “Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement de la Generalitat de Catalunya” (2017SGR595). We thank Foundation Dormeur for financial support for the acquisition of the QuantStudio-5 real time PCR system. JM-P was supported by the Spanish Ministry of Science,Innovation and Universities (grants PID2022-139271OB-I00 and CB21/13/00063, Spain), and Fundació La Marató de TV3 (grant 202120-30-31-32, Spain). Funded in part by the European Union. The PCR-4-ALL and UNDINE projects have received funding under the Horizon Europe research and innovation programme (grant agreement No 101095606 and No 101057100 respectively). CF-B and HP acknowledge support from the Spanish Ministry of Science and Innovation (MICINN) (PID2022- 142908OB-I00) and support from the grant CEX2023-0001290-S funded by MCIN/AEI/10.13039/501100011033, and support from the Generalitat de Catalunya through the CERCA Program. This research is part of the ISGlobal’s Program on the Molecular Mechanisms of Malaria which is partially supported by the Fundación Ramón Areces. We also acknowledged the internal funding from IrsiCaixa through the crowdfunding initiative YoMeCorono (JM-P) and ISGlobal (HP) to initiate these studies., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Proteomics of circulating extracellular vesicles reveals diverse clinical presentations of COVID-19 but fails to identify viral peptides

  • Gualdrón-López, Melisa
  • Ayllon Hermida, Alberto
  • Cortes Serra, Nuria
  • Resa Infante, Patricia
  • Bech Serra, Joan Josep
  • Aparici Herraiz, Iris
  • Nicolau Fernández, Marc
  • Erkizia, Itziar
  • Gutierrez Chamorro, Lucia
  • Marfil, Silvia
  • Pradenas, Edwards
  • Avila Nieto, Carlos
  • Cucurull, Bernat
  • Montaner Tarbes, Sergio Roberto
  • Fraile Sauce, Lorenzo José
Extracellular vesicles (EVs) released by virus-infected cells have the potential to encapsulate viral peptides, a characteristic that could facilitate vaccine development. Furthermore, plasma-derived EVs may elucidate pathological changes occurring in distal tissues during viral infections. We hypothesized that molecular characterization of EVs isolated from COVID-19 patients would reveal peptides suitable for vaccine development. Blood samples were collected from three cohorts: severe COVID-19 patients (G1), mild/asymptomatic cases (G2), and SARS-CoV-2-negative healthcare workers (G3). Samples were obtained at two time points: during the initial phase of the pandemic in early 2020 (m0) and eight months later (m8). Clinical data analysis revealed elevated inflammatory markers in G1. Notably, non-vaccinated individuals in G1 exhibited increased levels of neutralizing antibodies at m8, suggesting prolonged exposure to viral antigens. Proteomic profiling of EVs was performed using three distinct methods: immunocapture (targeting CD9), ganglioside-capture (utilizing Siglec-1) and size-exclusion chromatography (SEC). Contrary to our hypothesis, this analysis failed to identify viral peptides. These findings were subsequently validated through Western blot analysis targeting the RBD of the SARS-CoV-2 Spike protein's and comparative studies using samples from experimentally infected Syrian hamsters. Furthermore, analysis of the EV cargo revealed a diverse molecular profile, including components involved in the regulation of viral replication, systemic inflammation, antigen presentation, and stress responses. These findings underscore the potential significance of EVs in the pathogenesis and progression of COVID-19., The author(s) declare financial support was received for the research, authorship, and/or publication of this article. The proteomics of EVs isolated by CD9 was performed at the proteomics facility of Utrecht (Netherlands) as part of an EPIC-XS grant (0000205) to CT and HP. The proteomics analyses of EVs isolated by SEC were performed in the IJC Proteomic unit, which is part of the of Proteored, PRB3 and is supported by grant PT17/0019, of the PE I+D+i 2013-2016, funded by ISCIII and ERDF”. The CRG/UPF Proteomics Unit is part of the Spanish Infrastructure for Omics Technologies (ICTS OmicsTech), and it is supported by “Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement de la Generalitat de Catalunya” (2017SGR595). We thank Foundation Dormeur for financial support for the acquisition of the QuantStudio-5 real time PCR system. JM-P was supported by the Spanish Ministry of Science,Innovation and Universities (grants PID2022-139271OB-I00 and CB21/13/00063, Spain), and Fundació La Marató de TV3 (grant 202120-30-31-32, Spain). Funded in part by the European Union. The PCR-4-ALL and UNDINE projects have received funding under the Horizon Europe research and innovation programme (grant agreement No 101095606 and No 101057100 respectively). CF-B and HP acknowledge support from the Spanish Ministry of Science and Innovation (MICINN) (PID2022- 142908OB-I00) and support from the grant CEX2023-0001290-S funded by MCIN/AEI/10.13039/501100011033, and support from the Generalitat de Catalunya through the CERCA Program. This research is part of the ISGlobal’s Program on the Molecular Mechanisms of Malaria which is partially supported by the Fundación Ramón Areces. We also acknowledged the internal funding from IrsiCaixa through the crowdfunding initiative YoMeCorono (JM-P) and ISGlobal (HP) to initiate these studies.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Preclinical development of humanized monoclonal antibodies against CD169 as a broad antiviral therapeutic strategy

  • Resa-Infante, Patricia|||0000-0002-1727-592X
  • Erkizia, Itziar|||0000-0003-1244-8972
  • Muñiz-Trabudua, Xabier|||0000-0002-1142-4381
  • Linty, Federica
  • Bentlage, Arthur E.H.
  • Perez-Zsolt, Daniel|||0000-0003-4192-7622
  • Muñoz-Basagoiti, Jordana|||0000-0002-0384-5928
  • Raïch-Regué, Dàlia|||0000-0001-7656-5700
  • Izquierdo Useros, Nuria|||0000-0002-1039-1821
  • Rispens, Theo
  • Vidarsson, Gestur
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
New therapies to treat or prevent viral infections are essential, as recently observed during the COVID-19 pandemic. Here, we propose a therapeutic strategy based on monoclonal antibodies that block the specific interaction between the host receptor Siglec-1/CD169 and gangliosides embedded in the viral envelope. Antibodies are an excellent option for treating infectious diseases based on their high specificity, strong targeting affinity, and relatively low toxicity. Through a process of humanization, we optimized monoclonal antibodies to eliminate sequence liabilities and performed biophysical characterization. We demonstrated that they maintain their ability to block viral entry into myeloid cells. These molecular improvements during the discovery stage are key if we are to maximize efforts to develop new therapeutic strategies. Humanized monoclonal antibodies targeting CD169 provide new opportunities in the treatment of infections caused by ganglioside-containing enveloped viruses, which pose a constant threat to human health. In contrast with current neutralizing antibodies that bind antigens on the infectious particle, our antibodies can prevent several types of enveloped viruses interacting with host cells because they target the host CD169 protein, thus becoming a potential pan-antiviral therapy.